

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method of immunologically measuring the human medullasin content in blood comprising the following steps (a) and (b):

(a) breaking up the leukocytes in a blood sample by contacting said blood sample with the following aqueous ~~liquids~~ liquid (i) ~~or~~ ~~(ii)~~ or an aqueous liquid mixture of (i) and (ii)

(i) an aqueous liquid, which contains 0.05 mole % or more or 0.005 mole % or less of a solute, having an osmotic pressure of 250mOsm/kg•H<sub>2</sub>O or less or an aqueous liquid having an osmotic pressure of 310mOsm/kg•H<sub>2</sub>O or more;

(ii) an aqueous liquid comprising a hemolysate; and

(b) immunologically determining content of human medullasin in said blood sample by a method comprising contacting the blood sample containing said human medullasin released from the leukocytes broken up in said step (a) with an anti-human medullasin monoclonal antibody immobilized to an insoluble carrier in the presence of a labeled anti-human medullasin monoclonal antibody to form a sandwich complex and to capture the human medullasin on a

labeled immuno complex by an antigen-antibody reaction, and then determining the amount of activity of the label material in said complex.

2. (Previously Presented) The method of immunologically measuring the human medullasin content in blood according to claim 1, wherein said aqueous liquid (i) is a buffer solution and/or distilled water that may include a water-soluble organic solvent.

3. (Previously Presented) The method of immunologically measuring the human medullasin content in blood according to claim 1, wherein said aqueous liquid (i) is an aqueous solution containing a water-soluble substance selected from the group consisting of inorganic acid salts, organic acid salts, sugars, sugar alcohols, amino acids and protein substances.

4. (Previously Presented) The method of immunologically measuring the human medullasin content in blood according to claim 1, wherein the amount of said aqueous liquid (i) used is 50 to 100000 times that of the blood sample in terms of volume units.

5. (Previously Presented) The method of immunologically measuring the human medullasin content in blood according to claim 1 wherein said aqueous liquid (ii) is an aqueous solution of a surfactant.

6. (Previously Presented) The method of immunologically measuring the human medullasin content in blood according to claim 5, wherein said aqueous liquid (ii) is an aqueous solution of at least one type of hemolysate selected from the group consisting of higher fatty acid salts, alkylaryl sulphonates, alkyl sulphonates, alkyl sulphate ester salts, alkyl pyridinium salts, polyoxyethylene alkylphenyl ethers, polyoxyethylenealkylethers, polyoxyethylene sorbitan fatty acid esters and alkyl betaines.

7. (Previously Presented) The method of immunologically measuring the human medullasin content in blood according to claim 1 wherein the amount of aqueous liquid (ii) used is 50 times to 100000 times that of the blood sample in terms of volume units.

8. (Previously Presented) The method of immunologically measuring the human medullasin content in blood according to claim 1 wherein said step (b) of immunologically determining the content

of human medullasin in said blood sample comprises sandwiching said human medullasin in said blood sample between an anti-human medullasin monoclonal antibody immobilized to an insoluble carrier and a labeled anti-human medullasin monoclonal antibody to form a complex by an antigen-antibody reaction, and determining the amount of label in said complex.

9.-19. (Canceled)

20. (Currently Amended) A method of immunologically measuring the human medullasin content in blood comprising the following steps (a) and (b):

(a) breaking up the leukocytes in a blood sample by contacting said blood sample with the following aqueous ~~liquids~~ liquid (i) ~~or (ii)~~ or an aqueous liquid mixture of (i) and (ii)

(i) an aqueous liquid having an osmotic pressure of 250mOsm/kg • H<sub>2</sub>O or less or an aqueous liquid having an osmotic pressure of 310mOsm/kg • H<sub>2</sub>O or more;

(ii) an aqueous liquid comprising a hemolysate selected from the group consisting of higher fatty acid salts, alkylaryl sulphonates, alkyl sulphonates, alkyl sulphate ester salts, alkyl pyridinium salts,

polyoxyethylene                      alkylphenyl                      ethers,  
polyoxyethylenealkylethers, polyoxyethylene sorbitan  
fatty acid esters and alkyl betaines; and

(b) immunologically determining content of human medullasin in said blood sample by a method comprising contacting the blood sample containing said human medullasin released from the leukocytes broken up in said step (a) with an anti-human medullasin monoclonal antibody immobilized to an insoluble carrier in the presence of a labeled anti-human medullasin monoclonal antibody to form a sandwich complex and to capture the human medullasin on a labeled immuno complex by an antigen-antibody reaction, and then determining the amount of activity of the label material in said complex.

21. (Previously Presented) The method of immunologically measuring the human medullasin content in blood according to claim 20, wherein the aqueous liquid contains 0.05 mole% or more or 0.005 mole% or less of a solute.

22. (New) The method of immunologically measuring the human medullasin content in blood according to claim 1, wherein the aqueous liquid mixture of (i) and (ii) is used in step (a).

23. (New) The method of immunologically measuring the human medullasin content in blood according to claim 1, wherein the aqueous liquid (i) is used in step (a).

24. (New) The method of immunologically measuring the human medullasin content in blood according to claim 20, wherein the aqueous liquid mixture of (i) and (ii) is used in step (a).

25. (New) The method of immunologically measuring the human medullasin content in blood according to claim 20, wherein the aqueous liquid (i) is used in step (a).